SCHEMBL24349278

SCHEMBL24349278

Cc1nc(COC(=O)N(C)C)sc1-c1cccc(-c2cc(F)c3nn[nH]c3c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 6/20 0.44
▸ GPR52 Q9Y2T5 3/20 0.33
▸ PPARD Q03181 5/20 0.33
▸ MAPT P10636 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ CDC7 O00311 1/20 0.31
▸ PLK4 O00444 1/20 0.31
▸ DYRK3 O43781 1/20 0.31
▸ ROCK2 O75116 1/20 0.31
▸ MAP4K4 O95819 1/20 0.31
▸ ROS1 P08922 1/20 0.31
▸ PRKACA P17612 1/20 0.31
▸ RPS6KB1 P23443 1/20 0.31
▸ MARK3 P27448 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ AKT1 P31749 1/20 0.31
▸ MAPK9 P45984 1/20 0.31
▸ CSNK1A1 P48729 1/20 0.31
▸ CSNK1D P48730 1/20 0.31
▸ CLK2 P49760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24349240 0.88 BPGM (0.47) BPGMGPR52PPARDMAPTRAB9A
SCHEMBL24349003 0.84 BPGM (0.51) BPGMPPARDMAPTKDM4ECDC7
SCHEMBL26704336 0.84 BPGM (0.41) BPGMMAPTKDM4EMAPK1
SCHEMBL24348976 0.83 BPGM (0.52) BPGMGPR52PPARDMAPTKDM4E
SCHEMBL26704310 0.82 BPGM (0.46) BPGMGPR52PPARDMAPTKDM4E
SCHEMBL24349408 0.82 BPGM (0.64) BPGMPPARDMAPTKDM4ECDC7
SCHEMBL24349237 0.82 BPGM (0.51) BPGMGPR52MAPTROCK2PRKACA
SCHEMBL24348921 0.82 BPGM (0.64) BPGMGPR52PPARDMAPTKDM4E
SCHEMBL24348977 0.81 BPGM (0.54) BPGMMAPTKDM4ECDC7PLK4
SCHEMBL24348054 0.81 BPGM (0.55) BPGMPPARDMAPTKDM4ECDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885GPR52 3680/4885PPARD 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback